Not forgetting the other compounds in development. I got criticised for advising pi's on here not to top slice when we are at these levels and sadly some did just that or sold out. In the coming weeks when investors understand the science and see what that potential could be we will look back at this and smile at the current MC.
I believe the current estimates for the size of the lupus market is up to $6 billion per annum. The only new drug approved for the treatment of lupus in the last 50 years is Benlysta which has severe shortcomings. Benlysta was 50% owned by Human Genome Sciences and GSK bought them out for over $3billion ($14.25 per share)
Leading experts in the treatment of lupus have already reported that they believe Lupuzor has significant benefits over Benlysta.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.